Kettering Health fully restores emergency operations after cyberattack
All Kettering Health emergency departments are now fully operational following a cyberattack that took its systems offline, according to a statement from the Dayton-based hospital group's website.
John Weimer, Kettering Health senior vice president and leader for incident command, said in a statement that emergency rooms at Kettering Health locations are now accepting both walk-in patients and those transported by first responders.
'This is another great milestone in our recovery process. Our teams have worked incredibly hard to bring imaging up, so we could end diversion in our emergency departments,' Weimer said.
The hospital group confirmed May 20 it was experiencing a cybersecurity attack due to unauthorized access to its network, according to a statement on Kettering Health's website.
Kettering Health first announced it was experiencing a system-wide technology outage around 10:30 a.m. that morning, limiting its ability to access "certain patient care systems" across the organization. All elective inpatient and outpatient procedures at its facilities were canceled.
Since the initial outage on May 20, teams across Kettering Health continue to restore all technology systems in the aftermath of unauthorized access that caused the cyberattack, according to their website.
'We're incredibly grateful to our community partners," Weimer said. "Especially GDAHA and Premier Health, for their support and to our own caregivers and staff who continue to develop temporary measures to boost our recovery and return to normal procedures."
This article originally appeared on Cincinnati Enquirer: Emergency operations restored at Kettering Health after cyberattack
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
AstraZeneca announces results from MATTERHORN Phase III trial of IMFINZI
Positive results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca's (AZN) IMFINZI in combination with standard-of-care FLOT chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival, EFS, versus chemotherapy alone. Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction, GEJ, cancers. In a planned interim analysis, patients treated with the IMFINZI-based perioperative regimen showed a 29% reduction in the risk of disease progression, recurrence or death versus chemotherapy alone. Estimated median EFS was not yet reached for the IMFINZI arm versus 32.8 months for the comparator arm. For the secondary endpoint of overall survival, a strong trend was observed in favor of the IMFINZI-based perioperative regimen. The trial will continue to follow OS, which will be formally assessed at the final analysis. Confident Investing Starts Here:
Business Insider
an hour ago
- Business Insider
Guardant Health presented results of largest study on ctDNA in colon cancer
Guardant Health (GH) presented results of the largest study to date evaluating circulating tumor DNA, ctDNA, in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant chemotherapy involving over 2,000 patients with stage III colon cancer with median follow-up of 6.1 years were presented at the 2025 American Society for Clinical Oncology Annual Meeting. Results demonstrated that circulating tumor DNA detected in the bloodstream after cancer surgery and prior to the start of adjuvant therapy, using the Guardant Reveal test, is a strong predictor of the risk of disease recurrence and poorer survival, and suggest the potential for ctDNA testing to improve decision-making at a critical time point for post-operative chemotherapy. Specifically: Among patients with post-surgical ctDNA detected, 62.6% had the cancer return within 3 years, despite having had adjuvant chemotherapy, while only 15.4% of patients with undetectable ctDNA recurred in the same period. The level of ctDNA, or tumor fraction, showed promise in identifying individuals who are less likely to clear residual disease with adjuvant treatment.
2 hours ago
Bangladesh opens trial of deposed ex-Prime Minister Sheikh Hasina
DHAKA, Bangladesh -- A special tribunal set up to try Bangladesh's ousted Prime Minister Sheikh Hasina began proceedings Sunday by accepting charges of crimes against humanity filed against her in connection with a mass uprising in which hundreds of students were killed last year. The Dhaka-based International Crimes Tribunal directed investigators to produce Hasina, a former home minister and a former police chief before the court on June 16. Hasina has been in exile in India since Aug. 5, 2024, while former Home Minister Asaduzzaman Khan is missing and possibly also in India. Former police chief Chowdhury Abdullah Al Mamun has been arrested. Bangladesh sent a formal request to India to extradite Hasina in December. State-run Bangladesh Television broadcast the court proceedings live. Hasina and her Awami League party had earlier criticized the tribunal and its prosecution team for their connection with political parties, especially with the Jamaat-e-Islami party. In an investigation report submitted on May 12, the tribunal's investigators brought five allegations of crimes against humanity against Hasina and the two others during the mass uprising in July-August last year. According to the charges, Hasina was directly responsible for ordering all state forces, her Awami League party and its associates to carry out actions that led to mass killings, injuries, targeted violence against women and children, the incineration of bodies and denial of medical treatment to the wounded. The charges describe Hasina as the 'mastermind, conductor, and superior commander' of the atrocities. Three days after Hasina's ouster, Nobel Peace Prize laureate Muhammad Yunus took over as the nation's interim leader. The Yunus-led administration, which has already banned the Awami League party, amended relevant laws to allow for the trial of the former ruling party for its role during the uprising. In February, the U.N. human rights office estimated that up to 1,400 people may have been killed in Bangladesh over three weeks in the crackdown on the student-led protests against Hasina, who ruled the country for 15 years. The tribunal was established by Hasina in 2009 to investigate and try crimes involving Bangladesh's independence war in 1971. The tribunal under Hasina tried politicians, mostly from the Jamaat-e-Islami party, for their actions during the nine-month war against Pakistan. Aided by India, Bangladesh gained independence from Pakistan under the leadership of Sheikh Mujibur Rahman, Hasina's father and the country's first leader. In a separate development, Bangladesh's Supreme Court on Sunday cleared the path for the Jamaat-e-Islami party to regain its registration as a political party after a decade — a decision that would enable the party to take part in elections. The country's top court overturned a previous High Court verdict and said it is now up to the Election Commission to formally restore the registration of Bangladesh's largest Islamist party and their election symbol. Yunus said his administration would hold the election by June next year, but the Bangladesh Nationalist Party headed by former Prime Minister Khaleda Zia, Hasina's archrival, wants the election to be held in December this year. The relation between Zia's party, which is the largest in absence of Hasina's party, and the Yunus-led government has recently been frosty over the polls schedule.
